Galectin PhIIb NASH trial fails the primary goal, but researchers hammer on the positive
Before you get too deep into Galectin Therapeutics’ release on its Phase IIb data for its NASH drug, it’s important to keep in mind that the trial failed. Otherwise, you might miss it in all the upbeat assessments the company has to offer.
Researchers did not find statistically significant results in reducing a measure of hepatic venous pressure gradient for its therapy in patients with NASH cirrhosis, failing the primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
